Artelo Biosciences (ARTL) vs Clearmind Medicine (CMND)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Clearmind Medicine is the larger company by market cap ($1.3 million vs $1.3 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ARTL | CMND |
|---|---|---|
| Share price | $1.39 | $2.63 |
| Market cap | $1.30M | $1.33M |
| 1-day change | -4.14% | -17.68% |
| EPS (TTM) | $-20.56 | $-461.20 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | $-12.88M | $-3.86M |
| 52-week high | $179.19 | $649.60 |
| 52-week low | $1.30 | $2.63 |
| Distance from 52-week high | -99.22% | -99.60% |
| Average volume | 476.69K | 55.57K |
| Shares outstanding | 937.18K | 507.40K |
| Employees | 7 | — |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Artelo Biosciences
ARTL stock →Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, develops and commercializes therapeutics that target lipid-signaling pathways in the United States. The company's product candidate pipeline includes ART27.13, a synthetic dual cannabinoid G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of cancer-related anorexia; and ART12.11, a cocrystal composition of cannabidiol and tetramethylpyrazine for the treatment anxiety, depression, post-traumatic stress disorder PTSD, epilepsy and insomnia, and other potential indications.
Health Care · Biotechnology: Pharmaceutical Preparations · 7 employees
About Clearmind Medicine
CMND stock →Clearmind Medicine Inc., a clinical stage pharmaceutical company, develops novel psychedelic medicines to treat under-served health problems. The company develops treatments for alcohol use disorders, binge drinking, and eating disorders, as well as weight loss, obesity, and metabolic syndrome, anxiety disorders, post-traumatic stress disorder, depression, and treatment resistant depression.
Health Care · Biotechnology: Pharmaceutical Preparations
ARTL vs CMND FAQ
Which is bigger, Artelo Biosciences or Clearmind Medicine?
Clearmind Medicine (CMND) is larger, with a market capitalization of $1.33M compared with $1.30M for Artelo Biosciences (ARTL).
Are Artelo Biosciences and Clearmind Medicine in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.